News and analysis of Biotech stocks. No buy or sell recommendations.

Visit SeekingAlpha Biotech Stocks

Cinryze Approved: A Significant Catalyst for Viropharma, Lev Pharmaceuticals

Posted on October 12, 2008

On late Friday, it was announced that Lev Pharmaceuticals' (LEVP.OB) prophylactic treatment for the rare but life-threatening disorder known as hereditary angioedema- HAE was approved by the FDA.This is the first treatment to be approved in the United States for HAE and will likely have an almost immediate impact on the bottom line and cash flows for Viropharma (VPHM), who is expected to close on its deal to acquire Lev Pharmaceuticals on October 23, 2008 (2 business days following Lev's shareholder vote)....

Original article link